Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. Cellectar Wts 19
CLRBW

Buy CLRBW Stock

CLRBW
See CLRBW stock price and Buy/Sell Cellectar Wts 19 with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
CLRBW

Cellectar Wts 19 (CLRBW)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About Cellectar Wts 19 (CLRBW)

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near...Read more
Market Cap
1 Year High
Volume
1 Year Low
Price to Earnings Ratio
Open
Dividend Rate
High
Dividend Yield
Low

Community

No one owns or watch CLRBW stock

CLRBW stock rating

What analysts recommend for CLRBW stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell

CLRBW price target

What analysts think CLRBW will be worth
Low $0
High $0
Current $0
Target $0

Buy CLRBW Stock

CLRBW
See CLRBW stock price and Buy/Sell Cellectar Wts 19 with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

No one owns or watch CLRBW stock
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.